We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NanoViricides - Nanobiotechnology
NNVC 4.000-1.0%Sep 22 4:00 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: donpat1/5/2018 12:58:52 PM
Read Replies (2) of 1214
ExThera Medical


As a patient's blood flows through the Seraph® Microbind® Affinity Blood Filter, it passes over proprietary microspheres coated with molecular receptor sites that mimic the receptors on human cells that pathogens use when they invade the body. Harmful substances are captured and adsorbed onto the device’s proprietary surface and thereby removed from the bloodstream without adding anything to the treated blood, which is returned to the patient’s body with blood cells intact. The adsorption media is a flexible platform that uses chemically-bonded, immobilized heparin for its unique binding capacity, and may be configured with optional supplemental adsorbents to accommodate evolved pathogens. The blood filter uses an inexpensive, naturally occurring blood-contacting surface that is anti-thrombogenic and anti-inflammatory, and which has been proven to be safe in other medical devices and implants.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext